全文获取类型
收费全文 | 16916篇 |
免费 | 943篇 |
国内免费 | 75篇 |
专业分类
耳鼻咽喉 | 121篇 |
儿科学 | 413篇 |
妇产科学 | 418篇 |
基础医学 | 2296篇 |
口腔科学 | 288篇 |
临床医学 | 1621篇 |
内科学 | 3772篇 |
皮肤病学 | 476篇 |
神经病学 | 1443篇 |
特种医学 | 374篇 |
外科学 | 1665篇 |
综合类 | 82篇 |
一般理论 | 11篇 |
预防医学 | 1841篇 |
眼科学 | 409篇 |
药学 | 1191篇 |
中国医学 | 74篇 |
肿瘤学 | 1439篇 |
出版年
2024年 | 13篇 |
2023年 | 130篇 |
2022年 | 258篇 |
2021年 | 581篇 |
2020年 | 312篇 |
2019年 | 500篇 |
2018年 | 545篇 |
2017年 | 363篇 |
2016年 | 363篇 |
2015年 | 484篇 |
2014年 | 693篇 |
2013年 | 924篇 |
2012年 | 1389篇 |
2011年 | 1520篇 |
2010年 | 828篇 |
2009年 | 646篇 |
2008年 | 1175篇 |
2007年 | 1168篇 |
2006年 | 1090篇 |
2005年 | 1086篇 |
2004年 | 930篇 |
2003年 | 859篇 |
2002年 | 795篇 |
2001年 | 121篇 |
2000年 | 91篇 |
1999年 | 98篇 |
1998年 | 133篇 |
1997年 | 110篇 |
1996年 | 76篇 |
1995年 | 82篇 |
1994年 | 74篇 |
1993年 | 50篇 |
1992年 | 48篇 |
1991年 | 45篇 |
1990年 | 37篇 |
1989年 | 29篇 |
1988年 | 33篇 |
1987年 | 25篇 |
1986年 | 21篇 |
1985年 | 23篇 |
1984年 | 22篇 |
1983年 | 19篇 |
1982年 | 15篇 |
1981年 | 17篇 |
1980年 | 18篇 |
1979年 | 15篇 |
1978年 | 12篇 |
1977年 | 11篇 |
1976年 | 10篇 |
1974年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Ojeda S Anguita M Delgado M Atienza F Rus C Granados AL Ridocci F Vallés F Velasco JA 《European journal of heart failure》2005,7(5):921-926
The objective of the study was to evaluate whether improvements obtained during an intervention programme were maintained after the programme was stopped. 153 patients discharged with a diagnosis of heart failure (HF) were randomized to either usual care or an intervention programme, which included patient education, consultation with the cardiologist and monitoring in the Heart Failure Unit. After an average period of 16+/-8 months, the intervention programme was stopped. One year later, all the patients were re-examined to assess HF readmissions, all-cause mortality, quality of life, and prescribed medical treatment. During the 16+/-8-month treatment period, patients in the intervention group had a lower rate of HF readmissions (17% vs. 51%, p<0.01), less all-cause mortality (13% vs. 27%, p=0.03), improvement in quality of life (1.5+/-0.8 vs. 1.9+/-1, p=0.03) and optimisation of medical treatment was achieved. One year after stopping the intervention, there was no difference in HF readmissions (28% vs. 25%, p=0.72), all-cause mortality (14% vs. 17%, p=0.64) and quality of life (1.7+/-0.9 vs. 1.8+/-1, p=0.24) between the groups. Survival and the probability of not being readmitted due to HF were similar in both groups. There was also a reduction in the use of beta-blockers and spironolactone in the intervention group. CONCLUSIONS: The positive effects of an intervention programme are clearly reduced when it is stopped, due to less strict control of the patients and a decrease in the use of drugs with proven efficacy in HF. 相似文献
993.
The role of inflammation as a pathogenic factor in the development of renal disease in diabetes 总被引:10,自引:0,他引:10
Conclusions The classical pathogenic vision of diabetes mellitus as a metabolic disorder has changed in the past years. Inflammation has
been demonstrated as an important factor in the development of this disease, and moreover, inflammatory pathways play pivotal
roles in the pathogenesis of diabetic complications. This new vision leads us to consider new therapeutic strategies. Modulation
of inflammatory processes in the setting of diabetes may be an important therapeutic target with beneficial effects on diabetic
complications. 相似文献
994.
995.
For over two decades clinical studies have been conducted which suggest the existence of a relationship between depression
and Obstructive Sleep Apnea (OSA). Recently, Ohayon underscored the evidence for a link between these two disorders in the
general population, showing that 800 out of 100,000 individuals had both, a breathing-related sleep disorder and a major depressive
disorder, with up to 20% of the subjects presenting with one of these disorders also having the other. In some populations,
depending on age, gender and other demographic and health characteristics, the prevalence of both disorders may be even higher:
OSA may affect more than 50% of individuals over the age of 65, and significant depressive symptoms may be present in as many
as 26% of a community-dwelling population of older adults. 相似文献
996.
997.
This is a case of a 3-week-old male who presented to the emergency department with intermittent apnea and cyanosis. While in the emergency department, he had respiratory compromise with stress and required intubation. Further evaluation confirmed the diagnosis of a thyroglossal duct cyst. Congenital lesions causing extrinsic airway compression should be considered in all neonates with apnea, cyanosis, and respiratory compromise. Knowledge of pediatric airway anatomy and physiology is important in all cases where obstructive apnea is suspected. 相似文献
998.
Poor response to desmopressin acetate (DDAVP) in children with Hermansky-Pudlak syndrome 总被引:1,自引:0,他引:1
Cordova A Barrios NJ Ortiz I Rivera E Cadilla C Santiago-Borrero PJ 《Pediatric blood & cancer》2005,44(1):51-54
BACKGROUND: Hermansky-Pudlak syndrome (HPS) is a common genetic disorder in Puerto Rico. In children with HPS, bleeding is the most disturbing and incapacitating problem. Desmopressin (1-deamino-8-D-arginine vasopressin, (DDAVP)) has been recommended in the management of bleeding disorders characterized by platelet dysfunction, such as HPS. METHODS: Nineteen pediatric Puerto Rican patients with HPS and prolonged bleeding time (BT) were tested for response to administration of DDAVP. RESULTS: Baseline BT was abnormal in 18 (95%) of the patients. The BT following DDAVP administration improved in two cases (11%): one from 7.2 to 5.6 min and the other from 8 to 6 min (Tables II and III). BT measurements remained very prolonged (>15 min) in 17 (89%) of the patients. Patients with the HPS 1 gene mutation had a statistically significant correlation with the poor response following DDAVP (P = 0.03). CONCLUSIONS: DDAVP seldom improves the BT of Puerto Rican children with HPS. Response to DDAVP should be determined individually and platelet transfusion should remain the treatment of choice for a major bleeding episode or surgical procedure. 相似文献
999.
García-Suárez J de Miguel D Krsnik I Bañas H Arribas I Burgaleta C 《American journal of hematology》2005,80(4):271-281
The aims of this study were to evaluate the clinical characteristics of HIV-negative patients affected by lymphoproliferative disorders (LPD) who developed progressive multifocal leukoencephalopathy (PML), to delineate the risk factors, and to analyze whether the new antineoplastic therapies are changing the natural history of this infectious disease. We retrospectively analyzed 46 cases with confirmed LPD-associated PML published from 1958 to 2004. Patients were stratified according to two different time periods: group A included patients diagnosed before 1989, and group B included patients diagnosed since 1990, after introduction of purine analogues. Group A patients (n = 22) had received alkylating agents and/or radiotherapy, and the majority (63.6%) had advanced Hodgkin disease. At univariate analysis, uncontrolled Hodgkin disease was the only risk factor for PML. In group B patients (n = 24), the most frequent treatments received were purine analogues (58.3%) and high-dose therapy with hematopoietic stem cell transplantation (33.3%; HDT/HSCT). B-cell chronic lymphocytic leukemia (45.8%) and aggressive non-Hodgkin lymphoma (24.9%) were the most frequent underlying LPDs. Patients treated with purine analogues were more likely to have active LPD, lower CD4 cell counts, and to be older and male than were HSCT recipients. The median interval from purine analogues or HDT/HSCT to PML was 11 months. In HDT/HSCT recipients, this interval was delayed for 10 months when peri-transplantation rituximab was used. Univariate analysis identified age >55 years, male sex, and CD4 cell counts 相似文献
1000.
p130Rb2 and p27kip1 cooperate to control mobilization of angiogenic progenitors from the bone marrow
Vidal A Zacharoulis S Guo W Shaffer D Giancotti F Bramley AH de la Hoz C Jensen KK Kato D MacDonald DD Knowles J Yeh N Frohman LA Rafii S Lyden D Koff A 《Proceedings of the National Academy of Sciences of the United States of America》2005,102(19):6890-6895
Neoangiogenesis involves both bone marrow-derived myelomonocytic and endothelial progenitor cells as well as endothelial cells coopted from surrounding vessels. Cytokines induce these cells to proliferate, migrate, and exit the cell cycle to establish the vasculature; however, which cell cycle regulators play a role in these processes is largely unknown. Here, we report that mice lacking the cell cycle inhibitors p130 and p27 show defects in tumor neoangiogenesis, both in xenografts and spontaneously arising tumors. This defect is associated with impaired mobilization of endothelial and myelomonocytic angiogenic progenitors from the bone marrow. This article documents the role of these molecules in angiogenesis and further suggests that cell expansion and mobilization from the bone marrow of angiogenic precursors are separable events. 相似文献